retatrutide for menopause Retatrutide, an investigational triple hormone receptor agonist that shows promise weight loss in ongoing phase-3 clinical trials, is being sold openly across the internet and prescribed by licensed physicians online and retatrutide and menopause 8 Weeks

All authors have read and agreed to the published version of the manuscript

Graham SA, Pitter V, Hori JH, Stein N, Branch OH

Unlike traditional weight-loss medications that target only one metabolic pathway, Tirzepatide activates two key hormone receptors (GIP & GLP-1)

The most common side effect with this new medication like many medications is mild nausea, and it is not a stimulant, so those patients that have not been able to tolerate Phentermine or similar medications can take a GLP-1 medication alone to help with their appetite

For more detailed guidance on injection site selection and rotation, see our guide on where to inject retatrutide

Thank you